Delving into Chugai Pharmaceutical’s Multidimensional Optimization Process to Improve Both the Therapeutic Potential & the Manufacturability
Time: 4:00 pm
day: Day One
Details:
- Exploring FAST-Ig™, designed for efficient production of bispecific antibodies and ACTFc®, to improve antibody pharmacokinetics
- Applying these unique technology platforms to NXT007, a next-generation version of emicizumab for hemophilia A
- Discussing future directions for creating novel bispecific antibodies and beyond
